Insider buying last 90 days
No open-market insider purchases were filed for AXSM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AXSM insider filing, plotted on the chart in Gekko.Open AXSM in Gekko
NASDAQ: AXSM
Axsome Therapeutics (AXSM) Stock Analysis & Forecast
Sep 28 close
$193.89−1.20 (−0.6%)
Gekko Brief
AI summaryAxsome Therapeutics this week centers on its Alzheimer's agitation program, with new caregiver survey data on AUVELITY drawing analyst attention alongside a mixed round of rating actions. Morgan Stanley maintained its Equal-Weight rating while lowering its price target to $247 from $251, citing a competitive biotechnology landscape. In contrast, Truist Securities assumed coverage with a Buy rating and a $285 target, up from $200, and H.C. Wainwright reiterated a Buy rating at a $290 target following the survey results. These actions follow the company's Q2 2026 report of net product revenue of $218 million, up 46% year-over-year, with AUVELITY contributing $180.3 million and SUNOSI adding $35.8 million.
Shares closed at $193.89, down 0.6%, sitting between the 50-day average of $213.57 and the 200-day average of $199.09. The GekkoIndex reads 68.1, placing AXSM in the Accumulation zone. The stock trades 20.1% below Gekko Fair Value of $242.73.
Looking ahead, the next earnings report is due 2 November 2026, before the open, which falls 34 days out, beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a 0.6% return over 5 years, rising in 3 of them. Analyst consensus among 14 firms stands at 13 buys and 1 hold, with a consensus target of $285.40.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Axsome Therapeutics price vs fair value
Close $193.89200-day averageGekko Fair Value $242.73
Axsome Therapeutics quick facts
- Market cap
- $9.98B
- P/E ratio
- —
- Forward P/E
- 32.2
- EPS, TTM
- −$3.74
- Revenue, TTM
- $776.6M
- Profit margin
- -24.7%
- Dividend yield
- —
- Beta
- 0.71
- Volume
- 707,385 avg 608,669
- 1-year return
- +67.1%
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±9.8%
- 50-day average
- $213.57
- 200-day average
- $199.09
- Next earnings
- Nov 2 before open
- Shares outstanding
- 52.38M
Axsome Therapeutics swing-trade checklist
Axsome Therapeutics scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $193.89 sits between the 50-day ($213.57) and 200-day ($199.09) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
68.1, Accumulation
Reading 68.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
20.1% below
Price is 20.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 34 days
Next report Nov 2, 2026, 34 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.6% on average
From this point in the calendar, the next 20 trading days averaged +0.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Axsome Therapeutics stock chart and price history
Axsome Therapeutics closed at $193.89 on Sep 28, 2026, +67.1% over the past year, inside a 52-week range of $115.72 to $260.19.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −6.0%
- 3 months
- −19.6%
- 6 months
- +24.0%
- 1 year
- +67.1%
The full AXSM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AXSM in Gekko
Follow Axsome Therapeutics through every session
Put AXSM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AXSM in GekkoFree for 7 days. No credit card required.
About Axsome Therapeutics
Axsome Therapeutics works on developing treatments for disorders of the central nervous system, focused on patients in the United States. The company is best known for its pipeline of investigational drugs targeting conditions such as depression, Alzheimer's-related agitation, migraine, narcolepsy and fibromyalgia, with several candidates moving through Phase III trials at various stages of study.
Its work centers on advancing these compounds through clinical development rather than selling approved products, with each candidate aimed at a specific CNS condition. Axsome Therapeutics also collaborates with Duke University to study one of its compounds for use in smoking cessation, extending the potential applications of its research beyond the primary conditions it targets.
The company was founded in 2012 and is headquartered in New York, New York. Its shares trade on the NASDAQ under the ticker AXSM.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- axsome.com
Axsome Therapeutics GekkoIndex: the smart money zone
Axsome Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.1, in the Accumulation zone, up 7.1 points over five sessions.
68.1Accumulation
Up 7.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 20 | +1.9% | +12.3% | ||
| Accumulation (current zone) | 179 | +0.7% | +5.0% | ||
| Neutral | 416 | +0.8% | +2.6% | ||
| Distribution | 53 | +0.2% | −1.0% | ||
| Selling | 4 | Too few readings yet | |||
Average AXSM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the AXSM price, zone by zone.Track AXSM in Gekko
Is Axsome Therapeutics stock overvalued? Gekko Fair Value
Axsome Therapeutics trades 20.1% below Gekko Fair Value of $242.73, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Axsome Therapeutics shares are worth, recalculated every trading day.
$242.73
Gekko Fair Value, Sep 26, 2026
20.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open AXSM in Gekko
Axsome Therapeutics insider and Congress trading
No open-market insider purchases were filed for Axsome Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AXSM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AXSM, plotted on the chart in Gekko.Open AXSM in Gekko
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold AXSM.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Axsome Therapeutics earnings: next date and track record
Axsome Therapeutics reports on Nov 2, 2026, before the open (34 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 2, 2026
Expected before the open, 34 days away
- EPS estimate
- −$0.54
- Revenue estimate
- $258.0M
5 of 8reports beat the EPS estimate
±3.5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 10, 2026 AI summary
- What they said
- Axsome reported Q2 2026 net product revenue of $218 million, up 46% year-over-year. AUVELITY led growth at $180.3 million (+51% YoY, +18% QoQ), while SUNOSI contributed $35.8 million (+20% YoY). The company launched AUVELITY for Alzheimer's disease agitation and expanded its sales force. Net loss was $51.3 million ($0.99/share), with SG&A rising to $208.1 million due to commercialization investments. Cash stood at $320 million.
- Guidance
- Management expects AUVELITY growth to accelerate following the Alzheimer's disease agitation launch and sales force expansion. SUNOSI growth is expected to continue outpacing the market. SYMBRAVO gross-to-net discounts are expected to return to prior levels for the remainder of 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.99 est −$0.89 | $216.4M est $221.1M | +1.4% |
| May 4, 2026 | −$1.26 est −$0.86 | $189.4M est $190.9M | +8.0% |
| Feb 23, 2026 | −$0.56 est −$0.73 | $194.7M est $193.4M | −7.5% |
| Nov 3, 2025 | −$0.94 est −$0.82 | $171.0M est $191.3M | 0.0% |
| Aug 4, 2025 | −$0.92 est −$1.00 | $150.0M est $140.0M | +0.6% |
| May 5, 2025 | −$0.80 est −$1.26 | $121.5M est $140.4M | 0.0% |
| Feb 18, 2025 | −$0.96 est −$1.00 | $118.8M est $119.5M | −3.2% |
| Nov 12, 2024 | −$1.34 est −$1.38 | $104.8M est $98.37M | +7.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Axsome Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Axsome Therapeutics is $285.40, +47.2% from the last close, from 14 firms rating the stock in the last 90 days.
$285.40consensus 12-month target, +47.2% from the last close
Now $193.89Avg $285.40
Low $251High $380
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 25 | H.C. Wainwright | $290 | +49.6% |
| Sep 25 | Morgan Stanley | $251 | +29.5% |
| Sep 25 | Morgan Stanley | $251 | +29.5% |
| Sep 23 | Truist Financial | $285 | +47.0% |
| Sep 21 | H.C. Wainwright | $290 | +49.6% |
+5.0%average 20-day move after past Accumulation readings
+0.6%average move over the next 20 trading days in the last 5 years
±4.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Axsome Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Axsome Therapeutics averaged +0.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.2% | 2 of 5 |
| Next 10 trading days | −2.9% | 1 of 5 |
| Next 15 trading days | +5.1% | 4 of 5 |
| Next 20 trading days | +0.6% | 3 of 5 |
| Next 30 trading days | +11.4% | 4 of 5 |
For scale, AXSM’s typical 20-trading-day move in either direction is about 9.8%.
Axsome Therapeutics market cap and key statistics
Axsome Therapeutics’s market cap is $9.98B and revenue of $776.6M over the last twelve months.
Valuation
- Market cap
- $9.98B
- Forward P/E
- 32.2
- EPS, TTM
- −$3.74
- Gekko Fair Value
- $242.73
Trading
- Volume
- 707,385
- Avg volume, 20 days
- 608,669
- 52-week high
- $260.19
- 52-week low
- $115.72
- Shares outstanding
- 52.38M
Financials
- Revenue, TTM
- $776.6M
- Profit margin
- -24.7%
- Return on equity
- -245.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.71
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±9.8%
Axsome Therapeutics stock news this week
Coverage of Axsome Therapeutics this week reads positive: 9 positive, 2 neutral and 1 negative headlines.
- Is Axsome Therapeutics (AXSM) Undervalued As Caregiver Survey Data Tests Its CNS Growth Story?Simply Wall Street, Sep 27
- Axsome Therapeutics Is Maintained at Equal-Weight by Morgan StanleyMoomoo, Sep 26
- AXSM Maintains Rating by Morgan Stanley -- Price Target Lowered to $247GuruFocus, Sep 25
- AXSM Stock Price and Chart — NASDAQ:AXSMTradingView, Sep 25
- AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200Webull, Sep 25
- H.C. Wainwright reiterates Axsome stock Buy rating at $290 target By Investing.comInvesting.com Nigeria, Sep 25
Axsome Therapeutics peers
Axsome Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Axsome Therapeutics stock FAQ
What is Axsome Therapeutics’s market cap?
Axsome Therapeutics’s market cap is $9.98B at the Sep 28, 2026 close of $193.89, with 52.38M shares outstanding.
What is the Axsome Therapeutics stock forecast?
The consensus analyst 12-month price target for Axsome Therapeutics is $285.40, +47.2% from the last close. Of the 14 firms that rated the stock in the last 90 days, 13 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Axsome Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Axsome Therapeutics is undervalued: the Sep 28, 2026 close of $193.89 is 20.1% below Gekko Fair Value of $242.73. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Axsome Therapeutics report earnings next?
Axsome Therapeutics is expected to report on Nov 2, 2026, before the market opens (34 days away). Analysts expect earnings of −$0.54 per share on revenue of $258.0M. Axsome Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 3.5% on average across the report.
What is Axsome Therapeutics’s 52-week high and low?
Axsome Therapeutics’s 52-week high is $260.19 and its 52-week low is $115.72; it closed at $193.89 on Sep 28, 2026, +67.1% over the past year.
Is Axsome Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Axsome Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.